BiotechTube

Triptorelin Acetate 3.75mg intramuscular injection

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Deep Infiltrating Endometriosis (DIE)

Conditions

Deep Infiltrating Endometriosis (DIE)

Trial Timeline

Sep 16, 2013 → Jul 13, 2018

NCT ID
NCT01942369

About Triptorelin Acetate 3.75mg intramuscular injection

Triptorelin Acetate 3.75mg intramuscular injection is a pre-clinical stage product being developed by Ipsen for Deep Infiltrating Endometriosis (DIE). The current trial status is completed. This product is registered under clinical trial identifier NCT01942369. Target conditions include Deep Infiltrating Endometriosis (DIE).

What happened to similar drugs?

4 of 12 similar drugs in Deep Infiltrating Endometriosis (DIE) were approved

Approved (4) Terminated (2) Active (8)
✅Dalteparin sodium injection + WarfarinPfizerApproved
✅Low Molecular Weight Heparin (dalteparin)PfizerApproved
✅ApixabanPfizerApproved
✅ClexaneSanofiApproved
🔄Apixaban + Unfractionated Heparin (UFH) + WarfarinPfizerPhase 3
🔄Enoxaparin + Placebo + Apixaban + PlaceboBristol Myers SquibbPhase 3
🔄Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placeboBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01942369Pre-clinicalCompleted

Competing Products

20 competing products in Deep Infiltrating Endometriosis (DIE)

See all competitors
ProductCompanyStageHype Score
Edoxaban low dose + Edoxaban high doseDaiichi SankyoPhase 1
29
edoxaban tosylate + enoxaparin/unfractionated heparin + warfarinDaiichi SankyoPhase 2
35
Fragmin (dalteparin sodium )PfizerPre-clinical
26
FluconazolePfizerPre-clinical
26
Dalteparin sodium injection + WarfarinPfizerApproved
43
Low Molecular Weight Heparin (dalteparin)PfizerApproved
43
Apixaban + Unfractionated Heparin (UFH) + WarfarinPfizerPhase 3
40
ApixabanPfizerApproved
35
ApixabanBristol Myers SquibbPhase 2
35
Enoxaparin + Placebo + Apixaban + PlaceboBristol Myers SquibbPhase 3
40
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placeboBristol Myers SquibbPhase 3
40
ApixabanBristol Myers SquibbPre-clinical
26
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placeboBristol Myers SquibbPhase 3
40
EnoxaparinSanofiPre-clinical
26
ClexaneSanofiApproved
35
Idrabiotaparinux sodium + Idraparinux sodium + Avidin + Placebo (for Avidin)SanofiPhase 3
40
SanOrg34006 + LMW heparin + Unfractionated heparin + Vitamin K antagonist (VKA)SanofiPhase 3
40
Rivaroxaban (Xarelto, BAY59-7939) + Standard of careBayerPre-clinical
23
Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) + Unfractionated heparin + WarfarinBayerPhase 3
37
Rivaroxaban (Xarelto, BAY59-7939) + Recommended VTE pharmacological treatments according to international guidelinesBayerPre-clinical
23